FRANKFURT (Reuters) - Israel's Teva <TEVA.TA> has won the battle for German generic drugmaker Ratiopharm, paying an enterprise value of 3.625 billion euros to fix the industry leader's weakness in the world's second-largest generics market. Teva, which beat U.S. drugs powerhouse Pfizer <PFE.N> and Iceland's Actavis in the race ...

FRANKFURT/COLOGNE (Reuters) - The tussle over German generic drugs maker Ratiopharm is drawing to a close as the three remaining contenders square off in the final round of bidding, sources close to the deal told Reuters on Wednesday. Pfizer <PFE.N> will submit its bid on Wednesday, a person briefed on the matter said. Rival bidder Actavis of ...

Pfizer Inc. said Thursday the cancer drug Sutent did not meet key goals in two late-stage studies focusing on advanced breast cancer. The drug is already sold as a treatment for advanced kidney cancer and gastrointestinal stromal cancer, which affects the stomach. Both breast cancer studies ...

Two of the world's biggest pharmaceutical companies said Tuesday they are uniting their animal health businesses in a deal to become the top dog in the veterinary industry. Merck & Co. and France's Sanofi-Aventis SA said they'll jointly own the combined business, which will have ...